-
Sanofi Commences Negotiations with CD&R for Potential Sale of Opella Stake
•
Sanofi (EPA: SAN; NASDAQ: SNY) has initiated negotiations with private equity firm CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business, marking a significant milestone in the French pharmaceutical giant’s strategic realignment. While no decision has been finalized, Sanofi will provide further updates…
-
SAMR Proposes Guidelines to Curb Commercial Bribery in Pharmaceutical Industry
•
The State Administration for Market Regulation (SAMR) has unveiled the “Guidelines for Compliance of Pharmaceutical Enterprises in Preventing Commercial Bribery Risks (draft proposal),” marking a significant step towards transparency and ethical business practices within the pharmaceutical industry. The public is invited to provide feedback on the draft until October 20.…
-
JD Healthcare and Genrix Bio Join Forces to Revolutionize Patient Care and Pharmacy Services
•
JD Healthcare, a subsidiary of China’s e-commerce juggernaut JD.com (NASDAQ: JD), has formed a strategic partnership with Chongqing Genrix Bio Pharmaceutical Co., Ltd. This alliance combines Genrix Bio’s prowess in drug research and development with JD Healthcare’s extensive resource and ecological advantages in medical treatment, medication, health management, and insurance.…
-
Guangdong Province Aims for RMB One Trillion in Biopharma Industry Growth by 2027
•
The People’s Government of Guangdong Province has unveiled an ambitious “Action Plan for Further Promoting the High Quality Development of the Biomedical Industry in Guangdong,” with the aim of expanding the province’s biopharmaceutical and health industry cluster to a scale exceeding RMB one trillion (USD 141.43 billion) by 2027. The…
-
Immupeutics Medicine Secures NMPA Approval for Personalized Liver Cancer Immunotherapy IPM001
•
Immupeutics Medicine, a pioneer in tumor immunotherapy based in Beijing, has announced that it has received clinical approval from the National Medical Products Administration (NMPA) for its proprietary therapy, IPM001. This marks a significant step forward in the field of cancer treatment in China. IPM001 is a groundbreaking multi-antigen targeted…
-
Eli Lilly & Co. Partners with Insitro to Leverage AI in Metabolic Disease Drug Development
•
Eli Lilly & Co. (NYSE: LLY), a stalwart of the US pharmaceutical industry, has inked three strategic agreements with California-based Insitro, a company at the forefront of machine-learning driven drug development. This collaboration aims to forge ahead with new therapies for metabolic diseases, with a particular focus on metabolic dysfunction-associated…
-
Pfizer’s Hympavzi Secures FDA Nod, Offering Novel Once-Weekly Treatment for Hemophilia B
•
Pfizer Inc. (NYSE: PFE) has scored a significant win with the US Food and Drug Administration’s (FDA) approval of its drug Hympavzi (marstacimab-hncq) for routine prophylaxis in adults and pediatric patients aged 12 and older with hemophilia A, characterized by a congenital deficiency of factor VIII (FVIII), or hemophilia B,…
-
Hetero and Gilead Sciences Partner to Expand Access to HIV Treatment in Low-Income Countries
•
Indian pharmaceutical company Hetero has announced a new partnership with US healthcare giant Gilead Sciences (NASDAQ: GILD), securing a non-exclusive, royalty-free voluntary licensing agreement to manufacture and distribute lenacapavir in 120 primarily low- and lower-middle income countries (LMICs). This marks a significant step in expanding access to this groundbreaking HIV-1…
ADC / XDC AstraZeneca Auto-immune AZ Biosimilars Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
